Publikationen

Medien, wissenschaftliche Publikationen und Konferenzbeiträge


Erfahren Sie mehr über NEO


New Oncology in den Fachmedien

  • Liquid biopsies transform lung cancer therapy. 2016. MedNous. April, Seite 13.
    pdf-Datei

  • Neue Technologie zur Tumordiagnostik. 2016. ÄrzteZeitung. Nr. 37-65D.
    pdf-Datei

  • Neue Technologie für die molekulare Tumordiagnostik: Nachweis aller relevanten Genveränderungen an einer Tumorprobe. 2015. Der Onkologe. Band 21, Heft 10.
    pdf-Datei

  • Molekulare Diagnostik beim nicht-kleinzelligen Bronchialkarzinom: Neue Technologie zum raschen Nachweis aller therapierelevanten Genanomalien. 2015. Der Pneumologe. Band 12, Heft 6.
    pdf-Datei

 

 


Ausgewählte wissenschaftliche Artikel von unseren Wissenschaftlern und Gründern

  • Müller JN et al. Concordance between comprehensive cancer genome profiling in plasma and tumor specimens. 2017. J Thorac Oncol. Accepted manuscript available online.
    https://doi.org/10.1016/j.jtho.2017.07.014



  • Heuckmann JM et al. Comprehensive Hybrid Capture-Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH. 2017. J Thorac Oncol 12(3):e22-e24.
    https://www.ncbi.nlm.nih.gov/pubmed/28215724











  • Scheffler M et al. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. 2015. J Thorac Oncol. 10:e40-3.
    http://www.ncbi.nlm.nih.gov/pubmed


  • Kloth M et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. 2015. Gut.
    http://www.ncbi.nlm.nih.gov/pubmed


  • Mazières J et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. 2015. J Clin Oncol. 33:992-9.
    http://www.ncbi.nlm.nih.gov/pubmed








  • Heuckmann JM et al. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibitor in lung cancer. 2012. J Clin Oncol. 30:3417-20.
    http://www.ncbi.nlm.nih.gov/pubmed


  • Peifer M et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 2012. Nat Genet. 44:1104-10.
    http://www.ncbi.nlm.nih.gov/pubmed


  • Chmielecki J et al. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. 2012. Genes Chromosomes Cancer. 51:54-65.
    http://onlinelibrary.wiley.com/doi/10.1002/gcc.20930/epdf



  • Weiss J et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. 2010. Sci Transl Med. 2:62-93.
    http://www.ncbi.nlm.nih.gov/pubmed


  • Chmielecki J et al. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. 2010. Nucleic Acids Res. 38:6958-96.
    http://nar.oxfordjournals.org/content/38/20/6985.long



  • Thomas RK et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. 2006. Nat Med. 12:852-5.
    http://www.ncbi.nlm.nih.gov/pubmed

 

 

 


Konferenzbeiträge

  • Mueller J et al. Comparison of genomic alterations derived from matched tumor tissue and liquid biopsy. WCLC 2016. Abstract P2.03b-081.
    AbstractPoster.


  • Wiest G et al. Detection of an EGFR Kinase Domain Duplication in a Lung Adenocarcinoma Patient by Liquid Biopsy using Hybrid Capture-based Next Generation Sequencing. DGHO 2016. Abstract 291.
    AbstractPoster.


  • Mueller J et al. Hybrid-capture based sequencing assays to detect novel alterations in BRAF from tissue and liquid biopsies. ESMO 2016. Abstract 2761.
    AbstractPoster.


  • Heukamp L et al. Detection of actionable genome alterations using hybrid capture based next generation sequencing technology- NEOplus and NEOliquid. ASCO 2016. Abstract e23181.
    Abstract


  • Menon R et al. Identification of Therapeutically Targetable Genomic Alterations in a cohort of patients with CUP using a Hybrid-Capture based Next Generation Sequencing Assay. AACR 2016. Abstract 152.
    Abstract. Poster.


  • Menon R et al. NEOliquid: Detection of KIF5B-RET fusions in liquid biopsy samples. ELCC 2016. Abstract 431.
    Abstract. Poster.


  • Menon R et al. Discovery of a Novel EGFR Resistance Mutation by Capture Based NGS Following AZD9291 Treatment. Oncol Res Treat 2016;39(suppl 1):120.
    Abstract. Poster.


  • Dziadziuszko R et al. Discrepancies Between ALK FISH and Capture Based NEOplus Diagnostics. WCLC 2015. Abstract 2748.
    Abstract. Poster.


  • Menon R et al. Successful AZD9291 Therapy Based on NEOliquid Detection of Circulating T790M in a Liquid Biopsy Sample. 2015. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Abstract B135.
    AbstractPoster.

 

 


Kontakt

Telefon

Büro und Administration:
+49 221 888 23 80
 

Adresse

NEO New Oncology GmbH
Gottfried-Hagen-Str. 20
51105 Köln

ImpressumDatenschutzerklärung

Newoncology.com verwendet Cookies, um die Website für Ihre Bedürfnisse zu optimieren. Wenn Sie sich auf dieser Seite bewegen, stimmen Sie der Verwendung zu.

ok